JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

NCT06505837 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

395

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer

Interventions

DRUG: JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy
DRUG: JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy

Sponsor

Shanghai Junshi Bioscience Co., Ltd.

Collaborators

[object Object]